Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts.
Cancer Chemother Pharmacol
; 45(4): 345-9, 2000.
Article
en En
| MEDLINE
| ID: mdl-10755324
ABSTRACT
PURPOSE:
To further evaluate the activity of irinotecan (CPT-11) plus 1,3-bis-(chloroethyl)-1-nitrosourea (BCNU) in the treatment of central nervous system tumor-derived xenografts in athymic nude mice.METHODS:
We report studies evaluating the schedule-dependence of this regimen in the treatment of the malignant glioma xenograft D-54 MG.RESULTS:
The combination of BCNU and CPT-11 showed the highest enhancement index (2.0-3.3) when BCNU was given on day 1 and CPT-11 was given on days 1-5 and 8-12. Delay of CPT-11 administration to day 3 or day 5 substantially decreased activity with enhancement indices of 1.6-1.8 and 0.6-1.0, respectively. Delay of BCNU administration to day 8 also reduced the CPT-11 activity with enhancement indices of 1.2-1.4.CONCLUSIONS:
These results suggest that the presence of a BCNU-induced adduct or possibly crosslink prior to administration of CPT-11 is critical for enhanced activity. Although the mechanism of this enhancement is not currently known, a phase I trial of CPT-11 plus BCNU for adults with recurrent malignant glioma based on these results is in progress.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Encefálicas
/
Camptotecina
/
Carmustina
/
Antineoplásicos Alquilantes
/
Glioma
/
Antineoplásicos Fitogénicos
Límite:
Animals
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Cancer Chemother Pharmacol
Año:
2000
Tipo del documento:
Article
País de afiliación:
Estados Unidos